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Abstract 
Patients suffering from autoimmune diseases are more susceptible to mental disorders yet, 
the existence of specific cellular and molecular mechanisms behind the co-morbidity of 
these pathologies is far from being fully elucidated. By generating transgenic mice 
overexpressing Annexin-A1 exclusively in T cells to study its impact in models of 
autoimmune diseases, we made the unpredicted observation of an increased level of 
anxiety. Gene microarray of Annexin-A1 CD4+ T cells identified a novel anxiogenic 
factor, a small protein of approximately 21kDa encoded by the gene 2610019F03Rik 
which we named Immuno-moodulin. Neutralizing antibodies against Immuno-moodulin 
reverted the behavioral phenotype of Annexin-A1 transgenic mice and lowered the basal 
levels of anxiety in wild type mice; moreover, we also found that patients suffering from 
obsessive compulsive disorders show high levels of Imood in their peripheral mononuclear 
cells. We thus identify this protein as a novel peripheral determinant that modulates 
anxiety behavior. Therapies targeting Immuno-moodulin may lead to a new type of 
treatment for mental disorders through regulation of the functions of the immune system, 
rather than directly acting on the nervous system. 
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The challenging life of patients diagnosed with autoimmune diseases is often further 
impoverished by the emergence of mental disorders as a major co-morbidity (Coutinho 
and Vincent, 2016; Khandaker et al., 2017). For instance, if we only consider multiple 
sclerosis,  ~40% of patients suffering from this disease have attempted suicide (Feinstein 
and Pavisian, 2017; Pompili et al., 2012). The incidence of as major depression are 
significantly higher and is correlated with the progression of the disease (Lorefice et al., 
2015). Finally, a large study conducted on more than 4000 subjects enrolled on the UK 
Multiple Sclerosis Register showed that anxiety and depression were notably high, with 
54.1% of patients scoring > 8 for anxiety and 46.9% scoring >8 for depression on the 
Hospital Anxiety and Depression Scale (HADS)(Jones et al., 2012).  
Similar observations have been made for other autoimmune conditions. More than 30% of 
patients affected by autoimmune hepatitis suffer from schizophrenia (Butt et al., 2006; 
Cournos et al., 2005). Meta-analysis studies on the prevalence of depression and anxiety 
in rheumatoid arthritis (Matcham et al., 2013) or  systemic lupus erythematosus (Moustafa 
et al., 2020) patients have revealed a high variability in the prevalence of anxiety or major 
depression but in any case ranges of incidence from about  10 to 80% depending on the 
scale that was used. Most strikingly, immunomodulatory therapies for the treatment of 
autoimmune conditions might aggravate the emergence of these problems (Bosche et al., 
2015) thus presenting both clinicians and patients with a paradoxical dilemma: the 
physical symptoms of autoimmunity might be effectively improved at the expenses of a 
worsening of the emotional state and wellbeing. This is for instance the case of interferon 
beta (IFN-β) that is currently used as an effective treatment for multiple sclerosis but its 
use is limited by the increased incidence of suicidal thoughts in a significant proportion of 
patients (Goeb et al., 2006). Although some studies have investigated the functional cross-
talk between the brain and the immune system (Dantzer, 2018; Marin and Kipnis, 2017) it 
is still not clear how one system influences the other and if there is a common root or 
determinant for the emergence of mental disorders in autoimmune conditions.  
Annexin-A1 (AnxA1) is an endogenous modulator of a variety of physiological and 
pathological processes ranging from inflammation (Leoni and Nusrat, 2016; Perretti and 
D'Acquisto, 2009) and cancer (Boudhraa et al., 2016; Guo et al., 2013; Moraes et al., 
2018). As with many other multifunctional mediators, AnxA1 plays a homeostatic role in 
the immune system as it can exert both positive and negative functions depending on the 
contexts. In the context of T cells, studies have indeed provided contrasting and opposite 
results showing that it can act as both a positive (D'Acquisto et al., 2007a; D'Acquisto et 
al., 2007b; D'Acquisto et al., 2013; Huang et al., 2016; Huggins et al., 2009; Mihaylova et 
al., 2017; Paschalidis et al., 2010; Paschalidis et al., 2009; Sena et al., 2016; Tzelepis et 
al., 2015) and a negative modulator of T cell activation (Odobasic et al., 2018; Sena et al., 
2016; Yang et al., 2013; Yazid et al., 2015). All these studies have been done using either 
exogenously administered recombinant AnxA1 (and its mimetic) or AnxA1-deficient mice 
where the protein is absent in every immune cell. Aiming to address these controversies, 
we have generated a T cell specific AnxA1 transgenic mouse colony (AnxA1tg) to address 
the biology of this mediator.  
In this paper, analysis of AnxA1tg response in experimental model of autoimmunity 
showed exacerbated signs of inflammation. However, besides their autoimmune-prone 
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phenotype, AnxA1tg mice displayed an unexpected high level of compulsive digging that 
was noticeable even in their home cage and at basal physiological settings e.g. in mice that 
were not subjected to any inflammatory condition. Further exploration on the molecular 
mechanisms behind this phenotype of anxiety led us to the discovery of a new homeostatic 
modulator that we named Immuno-moodulin (Imood) - because of its discovery in T cells. 
Immuno-moodulin levels in mice affect their intrinsic basal level of anxiety. In addition, 
we found that patients suffering from OCD present high levels of Imood in their peripheral 
blood mononuclear cells. The results of this study expand our knowledge of the complex 
interactions and intersection between the immune and the central nervous system.  
Materials and Methods 
Reagents 
Unless otherwise stated, all the chemicals were purchased from Sigma. For the 
convenience of the readers all the antibodies used in the study have been reported in Table 
4 as well as in the figure legends.  
Animals and husbandry 
Wild type C57BL/6J (B6-CD45.2) and B6.SJL-Ptprca Pepcb/BoyJ (B6-CD45.1) were 
purchased from Charles River. AnxA1tg mice were generated in the in-house transgenic 
mouse facility of Queen Mary University of London by pronuclear injection. 
Mice were housed in groups of 6 per cage under specific-pathogen-free conditions and 
with free access to food and water. Mice were housed for at least 7 days prior to testing. 
All experiments were performed during the light phase of the light-dark cycle and no more 
than 2 tests per day were performed. The results presented in this manuscript were 
obtained using male mice (6-8 weeks old) because - unlike in humans - both the intensity 
and incidence of inflammatory/autoimmune disease are more pronounced in male mice. 
However, the difference we observed in terms of both immune response and behavioral 
changes were confirmed and reproducible in female mice (data not shown). All tests were 
conducted under license from the Home Office and according to the UK Animals 
(Scientific Procedures) Act, 1986. All experiments were approved and performed under 
the guidelines of the Ethical Committee for the Use of Animals, Bart’s and The London 
School of Medicine and Home Office Regulations (57) (PPL 80/8714). 
To monitory the transgenic colony, genomic DNA were extracted from ear clips by using 
REDExtract N-AMP –XNAT kit (Sigma, UK) and analysed by PCR with the following 
s p e c i f i c p r i m e r s f o r A n x A 1 t g : f o r w a r d p r i m e r 5 ’ -
G TAT G G A AT C T C T C T T T G C C A A G C - 3 ’ ; r e v e r s e p r i m e r i s 5 ’ -
ACHGATATGCACATCAGGAGGG-3’ (Thermo Scientific, UK). The parameters of the 
PCR reactions are: initial denaturation at 94ºC for 3min followed by 30 cycles of 
denaturation at 94ºC for 45sec, annealing at 60ºC for45sec and extension time at 72ºC for 
15sec, and afterwards a final extension step at 72ºC for 7 min.  
All the behavioral tests were video-recorded and analyzed double-blind during the light 
phase of the light-dark cycle, as previously described(McIlwain et al., 2001). The scoring 
and analysis of the data was hand-made by at least 2 blinded independent experimenters. 
All the efforts were made to minimize mouse discomfort in these behavioral experiments. 
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Mice were brought to the testing room at least 30 minutes before the start of the test 
session to allow habituation to the testing environment. All behavioral equipment was 
thoroughly cleaned and sanitized at the end of the day and in between tests. Unless 
otherwise specified, standard lighting (about 50 lux) and quiet conditions were maintained 
throughout each experiment. 
Generation of T cell-specific AnxA1tg mice  
To generate the VACD2 AnxA1 FLAG transgenic mice, murine AnxA1 gene was 
extracted, amplified and tagged with the FLAG epitope. The gene was cloned in TOPO 
pcDNA3.1 vector for verification of its expression in vitro and finally subcloned in the 
VACD2 vector (Zhumabekov et al., 1995) for T cell specific expression in the mouse. 
Finally, the VACD2 AnxA1 FLAG construct was modified and purified for the pronuclear 
microinjection into the mouse genome.  
Flow cytometric analysis 
Single cell suspension of thymocytes or lymphocytes from spleen and lymph nodes were 
obtained as previously described (Paschalidis et al., 2010; Rattazzi et al., 2013). Briefly, 
tissues were gently desegregated in RPMI medium supplemented with 100U/ml of 
penicillin and streptomycin (PAA laboratories, Buckinghamshire, UK) using a 70µm mesh 
cell strainer (Falcon, UK) and the piston of a 5ml syringe. Cell suspensions from spleen 
and lymph nodes were layered onto Histopaque-1077 (Sigma-Aldrich, Dorset, England) in 
a ratio 3:1 and centrifuged at 400g for 10 mins to isolate mononuclear cells. The resulting 
buffy coat was collected and washed twice with RPMI supplemented with 100U/ml of 
penicillin and streptomycin (PAA laboratories, Buckinghamshire, UK) and then suspended 
in FACS buffer (phosphate-buffered saline containing 5% fetal calf serum and 0.02% of 
NaN2) for further analysis. Thymocytes were washed twice with RPMI supplemented with 
100U/ml of penicillin and streptomycin (PAA laboratories, Buckinghamshire, UK) and 
then suspended in FACS buffer. Aliquots of cell suspensions were used to evaluate the 
total number of cells using a standard hematocytometer. Cells were stained in 100 µl of 
FACS buffer containing the following fluorochrome-conjugated antibodies: anti-CD3 
(clone 145-2C11), anti-CD4 (clone GK 1.5), anti-CD8 (clone 53-6.7) (all from 
eBioscience, San Diego, CA, USA). Cells were labeled with the appropriate concentration 
of conjugated antibodies for 1 h at 4°C. After labeling, cells were washed and analyzed 
using FACScalibur flow cytometer. Results were analyzed using the FlowJoTM software 
(Tree Star, Ashland, OR, USA, Oregon Corporation).  
T cell activation assay 
Lymph node T cells (1x105 cells/200 µl) were incubated with medium alone or stimulated 
by plate-bound anti-CD3 (clone 145-2C11; eBioscience) and anti-CD28 (clone 37.51; 
eBioscience) for 24 hours in 96-well plates. For CD25 and CD69 upregulation, lymph 
node T cells were stimulated with plate-bound anti-CD3 and anti-CD28 as indicated in the 
figure. After 16 hours, the cells were stained with PE-conjugated anti-CD69 (clone 
H1.2F3) and FITC-conjugated anti-CD25 (clone PC61.5) diluted in FACS buffer (PBS 
containing 1% FCS and 0.02% NaN2). The polyclonal antibody against Tdrp (Imood) was 
purchased from Novusbio (catalogue number NBP1-93675). The secondary antibody was 
a goat anti-rabbit Alexa Fluor 488-conjugated IgG from Abcam (catalogue number 
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ab150077). Intact cells were gated by using forward and side scatter and analyzed with the 
FlowJoTM software (Tree Star, Ashland, OR, USA, Oregon Corporation). IL-2 production 
was measured after 24 or 48 hr of stimulation using a standard ELISA kit and according to 
the manufacturer’s instructions (eBioscience).  
Intracellular staining and cytometric bead assay 
Th cell phenotype was studied by intracellular staining. Lymphocytes were isolated from 
MOG35-55 immunized mice from peripheral lymphoid organs and spinal cord. 
Lymphocytes (10x106 cells/ml) from lymph nodes and spleen were cultured for 72 hours 
with either medium alone (CTRL) or with anti-CD3 (clone 145-2C11; eBioscience) and 
anti-CD28 (clone 37.51; eBioscience) antibodies (1µg/ml; plate bound) or with the 
specific antigen MOG35-55 (100µg/ml). At third day, the cells were pelleted and the 
supernatants stored at -20ºC. Subsequently, the cells were re-challenged with concanavalin 
A (ConA, 5µg/ml; Sigma) in presence of protein transport inhibitor Brefeldin A (1:1000; 
eBioscience) for 4 hours. Mononuclear cells isolated from the spinal cords instead were 
directly triggered with ConA and Brefeldin A after collection. 
Cells were pelleted and then stained for CD4 (clone GK 1.5; eBioscience) for half an hour 
and fixed with 1% PFA for 10 minutes. Thereafter, cells were permeabilized and stained 
for 30 min in permeabilization buffer (eBioscience) containing conjugated antibodies (all 
from eBioscience) for cytokines (dil: 1:250) such as IFNγ (clone XMG1.2), IL-17 
(eBioTC11-18H10.1), GM-CSF (clone MP1-22E9) and IL-10 (clone JES5-16E3). Finally, 
cells were washed and suspended in FACS buffer for flow cytometer analysis. 
Cytometric bead array 
Cytokine production was measured by bead-based analytic assay in flow cytometry. We 
used a custom-designed Mouse Th1/Th2/ Th17 /Th22 13plex kits  supplemented with 
antibody-bounded beads for GM-SCF and IL-23 (eBioscience). Each sample (25µl of cell 
culture supernatant) was incubated with 50µl bead mixture and 50µl mix of antibodies 
conjugated with biotin for 2h. After two washes, streptavidin PE conjugated antibodies 
was added and samples were let rocking for 1 hour in dark. Finally, samples were washed 
and stored overnight at 4ºC. Standards diluted serially for 7 times were prepared and 
processed at the same time. Samples were analysed using a BD LSR Fortessa using the 
following voltage settings: FSC 444, SSC 250, YG-585/15 channel 430, R-670/14 channel 
400. 
Histology  
Intact spinal cords were first fixed in 4% paraformaldehyde for 72 h and then  incubated 
with decalcifying solution containing EDTA (0.1 mM in PBS) for 14 days prior to paraffin 
embedding. Tissues sections (5 µm) were deparaffinized with xylene and stained with 
hematoxylin and eosin (H&E) by our in-house histology facility (https://
www.bci.qmul.ac.uk/en/research/lab-facilities/pathology). Photos of the sections were 
acquired using an Olympus BX61 available at the in-house pathology facility. In all cases, 
a minimum of three sections per animal was evaluated. Phase-contrast digital images were 
taken using the Image Image-Pro (Media Cybernetics, Rockville, MD, USA) analysis 
software package. 
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MOG35-55-induced Experimental Autoimmune Encephalomyelitis 
Male C57BL/6 mice received an intradermal injection of 300 µg of MOG35-55 
(MEVGWYRSPFSRVVHLYRNGK, synthetized by Cambridge Research Biochemicals, 
UK; Cambridge Research Biochemicals) emulsified in Complete Freund’s adjuvant (CFA; 
Sigma-Aldrich, Dorset, England) and two doses of 500ng of pertussis toxin (PTX; Sigma-
Aldrich, Dorset, England) at day zero and day two as previously reported (Paschalidis et 
al., 2009).  The severity of the disease was scored on a scale of 0 to 6 with 0= no 
neurological signs, 1=tail weakness, 2= tail paralysis, 3= loss of righting reflex (the mouse 
can no longer right themselves after being laid on their back), 4= hind leg paralysis, 5= 
quadriplegia and 6= death.  
Leukocytes isolation from central nervous system  
Vertebral columns were dissected from the lumbar to the cervical region and washed 
several times in PBS to remove blood trace. Spinal cords were extracted by hydro pressure 
in the spinal canal by using a 2ml syringe and 19-gauge needle. Subsequently, tissues were 
torn apart in sterile PBS by mechanical pressure through a 70µm mesh cell strainer 
(Falcon). Mononuclear cells and lymphocytes were isolated by density gradient 
centrifugation in Percoll (GE Healthcare). In detail, cells were pelleted at 400xg for 5 min 
and suspended in a 30% Percoll solution. The 30% Percoll solution was carefully layered 
onto a 70% Percoll solution in a ratio 1:2 and centrifuged at 500xg for 30 min. In this 
density gradient mononuclear cells sediment at the interface between 30% and 70% 
Percoll layers. About 2-3ml of interface solution was collected only after the fatty layer at 
the top of the centrifuge tube was carefully removed. The purified mononuclear cells were 
washed twice in RPMI supplemented with 100U/ml of penicillin and streptomycin and 
10% of FCS (Invitrogen).  
Pristane-induced lupus 
Wild type or AnxA1tg male mice received received a single 0.5 ml i.p. injection of sterile 
pristane (Sigma-Aldrich, St Louis, MO, USA). Weight was recorded every other day or 
every 3 days for over 5 weeks. In some experiments, mice were culled after 4 weeks and 
the spleen and lung collected for histological analysis. The weight of the spleen was also 
measured to compare the level of splenomegaly between wild type or AnxA1tg. 
Digging and marble-burying tests  
Marble-burying and digging tests were carried out as described previously (Gallo et al., 
2014) with some modifications. Briefly, mice were individually placed in a clear plastic 
box (48cm x 39cm x 31cm) filled with approximately 5-cm-deep wood chip bedding 
lightly pressed to give a flat surface. The same bedding substrate was used for all the mice 
and flattened after each test. Twenty glass marbles were placed on the surface in five rows 
of 4 marbles each. The latency to start digging, the number of digging bouts and the 
number of buried marbles (to 2/3 their depth) were recorded during the 10 min test.  
Climbing activity test  
The climbing test is used to assess vertical activity and exploratory behavior. The test was 
performed as previously described (Gallo et al., 2014). Briefly, mice were placed, one at a 
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time, on a thin layer of fresh wood chip bedding on a laboratory bench and covered with a 
cylindrical climbing mesh (60 cm x 30 cm base diameter). They were each observed and 
recorded for 5 minutes. The number of climbing events and total duration of climbing 
activity was assessed. The criterion for climbing was for a mouse to have all 4 feet on the 
wire mesh while a climb terminated as soon as one foot touched the bench. This test was 
conducted in the late afternoon, when mice are known to be more active.  
Light-dark shuttle box  
In this test exploratory activity reflects the combination of hazard and risk avoidance 
(Bourin and Hascoet, 2003) The apparatus consisted of a 45cm x 20 cm x 21 cm box, 
divided into two distinct compartments: one third (15 cm long) painted black, with a black 
lid on top, the remaining two thirds painted white and uncovered. A 2.5 cm x 2.5 cm 
opening joined the two compartments. One side of the bright box was transparent to 
enable behavioral assessment and the averseness of this compartment was increased by 
additional illumination supplied by a 50 W lamp placed 45 cm above the centre of the box 
floor. The test was performed in accordance with a previous published protocol (Bourin 
and Hascoet, 2003). Each mouse was placed in the bright compartment, facing away from 
the opening and allowed to explore the box for 5 minutes. Dependent variables included 
the time spent in the light area, latency to cross to the dark area (all four paws in) and the 
total number of transitions between compartments. The apparatus was cleaned after each 
trial.  
Open field activity test  
The open filed test was performed as described previously (Gallo et al., 2014). The open 
field consisted of a white PVC arena (50cmx30cm) divided into 10cmx10cm squares. 
Mice were brought into the experimental room 15min before testing. Each mouse was 
placed in one of the corner squares facing the wall, observed and recorded for 5min. The 
total number of squares crossed, latency to the first rear and the total number of rears were 
recorded. After each test, the arena was cleaned with water to attenuate and homogenize 
olfactory traces.  
Real-time polymerase chain reaction 
Total RNA was extracted from brains of wild type and AnxA1tg mice RNeasy Microarray 
Tissue Mini Kit (Qiagen, West Sussex, UK) while for the purified CD4+ T cells we used 
RNeasy Mini Kit from the same manufacturer. Meninges were removed by gently rolling 
the brains on Whatman paper. Total RNA was reverse transcribed using 2 mg oligo(dT)15 
primer, 10 U AMV reverse transcriptase, 40U RNase inhibitor (all from Promega 
Corporation, Madison, WI, USA) and 1.25mM each dNTP (Bioline, London, UK) for 45 
min at 42ºC. Real-time polymerase chain reaction was carried out by using ABsoluteTM 
QPCR ROX Mix (Thermo Scientific, Epsom, UK) and fluorescent QuantiTect primers 
(Qiagen, West Sussex, UK). The human and murine primers for Tdrp were HsTDRP1SG 
and MmTdrp1SG. Cycling conditions were set according to the manufacturer’s 
instructions. Sequence-specific fluorescent signal was detected by 7900HT Fast Real-
Time PCR System (Applied Biosystems, Warrington, Cheshire, UK). mRNA data were 
normalized relative to glyceraldehyde 3-phosphate dehydrogenase and then used to 
calculate expression levels. We used the comparative Ct method to measure the gene 
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transcription in samples. The results are expressed as relative units based on calculation of 
2-ΔΔCt, which gives the relative amount of gene normalized to endogenous control 
(glyceraldehyde 3-phosphate dehydrogenase) and to the sample with the lowest expression 
set as 1. 
Total RNA was also isolated from PBMCs of OCD subjects and healthy controls 
according to the method of Chomczynski and Sacchi (Chomczynski and Sacchi, 1987) RT-
PCR reactions were performed using the RevertAid H Minus First Strand cDNA Synthesis 
Kit (Thermo Scientific, Waltham, MA, USA). The relative abundance was assessed by RT-
qPCR using iQ SYBR Green Supermix (Hercules, CA, USA) on a DNA Engine Opticon 2 
Continuous Fluorescence Detection System (MJ Research, Waltham, MA, USA). To 
provide precise quantification of the initial target in each PCR reaction, the amplification 
plot was examined and the point of early log phase of product accumulation defined by 
assigning a fluorescence threshold above background, defined as the threshold cycle 
number or Ct. Differences in threshold cycle number were used to quantify the relative 
amount of the PCR targets contained within each tube. After PCR, a dissociation curve 
(melting curve) was constructed in the range of 60 to 95 °C to evaluate the specificity of 
the amplification products. The relative expression of different amplicons was calculated 
by the delta-delta Ct (ΔΔCt) method and converted to relative expression ratio (2−ΔΔCt) for 
statistical analysis. All human data were normalized to the endogenous reference genes β-
actin and GAPDH combined. 
Microarray analysis  
Total RNA was hybridized to Affymetrix Mouse Gene 1.0 ST array chips at UCL 
Genomics (London, UK) with standard Affymetrix protocols, using GeneChip Fluidics 
Station 450, and scanned using the Affymetrix GeneChip Scanner (Affymetrix, Santa 
Clara, CA, USA). Computational analysis was performed using Mac OS 10.6.8, and R 
version 3.1.0. affymetrix platform MoGene_1.0st transcript cluster. Heatmap was 
generated by the function heatmap.2 of the CRAN package, gplots, using the complete-
linkage clustering using the Euclidean distance. Data was normalized by robust multiarray 
average (RMA) of the Bioconductor package, affy. Relevant genes were filtered by 
excluding those without an Entrez ID and those with low expression levels less than 100 
by non-logged value. T-statistics were applied across the data set using the Bioconductor 
package Limma considering the false discovery rate and differentially expressed genes 
were identified by P < 0.05 (non-adjusted P value).  
Western blotting analysis 
Lymph node and splenic T cells or purified CD4+ T cells were stimulated as indicated in 
figures. To obtain the whole cell lysate, cells were resuspended in ice-cold lysis buffer 
(1% NP-40, 20 mM Tris pH 7.5, 150 mM NaCl, 1 mM MgCl2, 1 mM EGTA, 0.5 mM 
PMSF, 1 µM aprotinin, 1 µM leupeptin, 1 µM pepstatin, 50 µM NaF, 1 µM NaVO4, 1 µM 
µ-glycerophosphate) and left on ice for 5 mins. Cell lysates were centrifuged at 13,000 
rpm at 4ºC for 5 mins and the post-centrifugation supernatants collected, mixed with 
6×Laemmli buffer (Invitrogen) and stored at -20°C.  
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To immunoprecipitate extracellular released Imood, 5 µl of rabbit polyclonal antibody 
against Tdrp (Novusbio; catalogue number NBP1-93675) and 35 µl of protein A/G 
sepharose beads (Santa Cruz) were added to 500 µl of culture supernatants obtained from 
1x107/ml CD4+ T cells stimulated with plate-bound anti-CD3/CD28 (1µg/ml) for 24 hrs. 
Samples were incubated overnight at 4°C under continuous rotation and then washed with 
cold PBS for 3 times. Soon after the washes, samples were denatured with 35ml of 
6×Laemmli buffer (Invitrogen).  
Lysates and immunoprecipitates were subjected to electrophoresis on SDS-12% poly-
acrylamide gel (Novagen). After subsequent transfer onto polyvinylidene difluoride 
Immobilon-P Transfer membranes (Millipore, Watford, UK), these were incubated 
overnight with antibodies diluted in Tris-buffered saline solution containing Tween-20 
(TTBS: 130 mM NaCl; 2.68 mM KCl; 19 mM Tris-HCl; 0.001% v/v Tween-20, pH 7.4) 
with 5% nonfat dry milk (Marvel) at 4°C. Immunoblotting and visualization of proteins by 
enhanced chemiluminescence (ECL; Amersham Biosciences, Piscataway, NJ, USA) were 
performed according to manufacturer’s instructions. The recombinant Tdrp used as 
positive control was purchased from Origene (https://www.origene.com; Recombinant 
protein of human chromosome 8 open reading frame 42 (C8orf42), catalogue number 
TP313199). 
Genetic Immunization  
Genetic immunization is an antibody generation platform offered as service by Aldveron 
(http://www.aldevron.com). This technology is most suitable to generate neutralising 
antibodies because native proteins are expressed in vivo with normal posttranscriptional 
modifications. The target is cloned into one of Aldveron proprietary immunization vectors 
and introduced into the host organism for gene expression. To help identify positive 
antisera and hybridomas, screening without purified antigen is made possible with the use 
of Aldveron proprietary screening vectors. 
The procedure followed for the generation of 1B10 and 1C4 is herein briefly described. 
Six rats were immunised with the immunisation vector pB8-TDRP-mur containing TDRP 
cDNA sequence. The immune serum was taken at day 24 of the immunisation protocol, 
after 4 genetic applications. Sera, diluted in PBS 3% FBS, were tested by flow cytometry 
using mammalian cells transiently transfected with the murine Tdrp cDNA cloned into an 
Aldevron proprietary expression vector (pB1-TDRP-mur). A goat anti-rat IgG R-
phycoerythrin conjugate (Southern Biotech, #3030-09) at 10 µg/ml was used as a 
secondary antibody. As negative control, mammalian cells transfected with an irrelevant 
cDNA cloned in the same expression vector were used. Cell surface expression of the 
screening vector pB1-TDRP-mur was analysed by flow cytometry using an anti-tag 
antibody and a goat anti-mouse IgG R-phycoerythrin conjugate (Southern Biotech, 
#1030-09) at 10 µg/ml as a secondary antibody. 
Subjects 
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23 OCD outpatients of either gender and any age, treated and followed up at the OCD 
tertiary outpatient Clinic of the University Department of Psychiatry of Milan, Policlinico 
Hospital, were included in the study. Diagnoses were assessed by the administration of a 
semi-structured interview based on DSM-5 criteria (SCID 5 research version, RV). In case 
of psychiatric comorbidity, OCD had to be the primary disorder, causing the most 
significant distress and dysfunction and providing the primary motivation to seek 
treatment. Patients were excluded from the study if they had recent or current alcohol or 
substance abuse (last 3 months), as well as medical conditions including autoimmune 
diseases, due to their potential influence over gene expression. For the same reason, 
lifetime history of trauma (according to DSM-5), as well as the current presence of 
relevant psychological stress, were considered exclusion criteria. Clinical assessment 
included the collection of the following demographic and clinical variables: gender, age, 
age at onset, and current pharmacological treatment. In addition, illness severity was 
measured through the Yale-Brown Obsessive-Compulsive Scale. Patients had maintained 
their pharmacological treatment stable for at least one month in order to be enrolled in the 
study and on the day of collection of blood. Control subjects (n = 20) were volunteers 
matched for gender, age and ethnicity, with no psychiatric diagnosis as determined by the 
SCID 5 and no positive family history for major psychiatric disorders in the first-degree 
relatives (as assessed by the Family Interview for Genetic Studies). Blood collection was 
performed between 2 and 4 pm from  fasting donors. PBMCs were separated by density 
gradient using the Lympholyte-H kit as recommended by the manufacturer (Cedarlane 
Laboratories, Canada). All subjects had given their written informed consent to participate 
to the study, which included the use of personal and clinical data as well as blood drawing 
for genotyping and methylation analysis. The study protocol had been previously 
approved by the local Ethics Committee.  
Statistics 
According to the nature of the data obtained, a Student’s t test (2-tailed), or a 1 or 2-way 
analysis of variance (ANOVA) was performed. Time-course observations were analysed 
with two-way ANOVA followed by Bonferroni multiple-comparison test. Behavioural data 
was analysed via nonparametric analysis using the Mann-Whitney U test. All statistical 
analysis was performed using GraphPad PRISM software v8.0, with the exception of 
microarray analysis which was carried out as stated in 2.13.3 using the software package 
LIMMA (Bioconductor). Data was analysed for normality using the D’Agostino-Pearson 
omnibus normality test. 
Results  
Generation and phenotypic characterization of T cell specific AnxA1tg mice  
We generated T cell specific transgenic mice through pronuclear injection of VACD2 
AnxA1 FLAG construct in 129 FVB mice (Supplementary Figure 1). Both the two 
founders and their litters showed no gross sign of disease. Following backcrossing onto 
C57BL/6 background and intercross to generate mice with the transgene on both alleles, 
we noticed that the female litters from one of the two transgenic founders presented an 
unusual high incidence (almost 80%) of maternal cannibalism. This was successfully 
controlled by administering perphenazine (0.025 mg/ml in drinking water) during 
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pregnancy as it has been previously reported for other autoimmune prone and highly 
anxious mouse strains such as the DBA/2J (Carter et al., 2002). Rescued newborn pups 
from this line (called ‘the red line’) had often to be raised by C57BL/6 foster mothers to 
avoid losing the colony. The combined administration of perphenazine and fostering care, 
made this line challenging to use. Therefore, unless otherwise stated, all the experiments 
were carried out using the litters of the other founder. Analysis of the immune repertoire of 
AnxA1tg mice from both founders showed no significant differences in lineage 
commitment towards CD4+ or CD8+ cells in all lymphoid organs (Supplementary Figure 
1A). To assess if AnxA1 overexpression in T cells would have any effects on the 
cellularity of the lymphoid organs we measured the total cell number of cells present in 
lymph nodes, spleen and thymus of AnxA1tg mice compared to control. As shown in 
Supplementary Figure 1B, no significant changes were found except in in lymph nodes 
where the cellularity was significantly higher (by about 60%) in AnxA1tg mice compared 
to control.  
Increased T cell activation and autoimmunity in AnxA1tg mice 
Consistent with our previous reports (D'Acquisto et al., 2007a; D'Acquisto et al., 2007b; 
Paschalidis et al., 2010; Paschalidis et al., 2009) AnxA1tg T cells showed a clear pro-
inflammatory phenotype as evidenced by lower threshold of CD25 and CD69 upregulation 
(Figure 1A) and increased production of IL-2 following anti-CD3 plus anti-CD28 (anti-
CD3/CD28) stimulation (Figure 1B). In vivo, AnxA1tg mice showed an exacerbated 
inflammatory response in the MOG35-55-induced experimental autoimmune 
encephalomyelitis (EAE) (Figure 1C) as evidenced by the exacerbated severity of the 
clinical score and increased weight loss after the onset of the disease (day 12) and larger 
inflammatory infiltrate of the spinal cord in AnxA1tg mice compared to wild type. No 
differences were observed in terms of disease incidence between control and AnxA1tg 
mice (Table in Figure 1C). The same exacerbated inflammatory response was observed 
and confirmed in the red line mice (Supplementary Figure 3A). To expand and confirm 
these findings in another model of autoimmune inflammation, we subjected AnxA1tg mice 
to an experimental model of systemic lupus erythematosus (Reeves et al., 2009). As 
shown in Figure 1D (right panel), injection of pristane to AnxA1tg mice provoked a 
significant weight loss over a period of 35 days while control mice gained about 30% of 
their initial weight over the same period. As the disease progresses, a number of organs, 
including the spleen and the lung, becomes enlarged or accumulate inflammatory infiltrate 
(Chowdhary et al., 2007; Freitas et al., 2017). As shown in Supplementary Figure 4A, 
AnxA1tg mice showed increased splenomegaly (spleen weight 0.130± 0.010 gr in wild 
type mice vs 0.281± 0.011 gr in AnxA1tg; n=5 mice, p<0.0001) with typical pathological 
features such as enlarged B-cell follicles and infiltration of oil droplets compared to 
control wild type mice. The lungs of AnxA1tg mice also showed increased areas of focal 
hemorrhages together with severe mixed inflammatory infiltrate compared to control 
(Supplementary Figure 4B).  Consistent with these results, ~ 30% of AnxA1tg mice died 
during the 35-day treatment while control animals showed a 100% survival (Figure 1D; 
left panel).  
Selective accumulation of Th1/Th17 double positive cells in the inflamed tissue of 
AnxA1tg mice 
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To further examine the activation state of AnxA1tg T cells in the EAE mice, we 
investigated the effector phenotype of these cells at day 9 (onset of the disease) and day 16 
(peak of the disease). This allowed us to distinguish the effects of AnxA1 overexpression 
during the priming phase occurring in the draining lymph nodes at day 9 or the 
differentiation phase occurring within the spinal cord at day 16 (Rossi and Constantin, 
2016). Comparison of the total cell number of CD45+ leukocytes in either lymph node or 
spinal cord of AnxA1tg and wild type mice showed no significant differences (Figure 2A 
and B, bottom panels).  Day 9 comparison of the draining lymph nodes of control and 
AnxA1tg mice showed a significant increase in the number of CD4+ T cells (by about 
85%) in the latter group, but no difference in the percentage of IL-17+/IFN-γ+  or IL-17+/
GM-CSF+ double-positive or single-positive T cells (Figure 2A). At day 16, the number 
of CD4+ T cells recovered from the spinal cord of was ~3-fold higher in AnxA1tg 
compared to control but in this case we observed an increase in the percentages of IFN-γ+/
IL-17+ (1.9 ± 0.12% in wild type vs 4.5 ± 0.21% in AnxA1tg; n=6, p<0.0001) or GM-
CSF+/IL-17+ (4.8 ± 0.19% in wild type vs 10.4 ± 0.45% in AnxA1tg; n=6, p<0.0001) 
pathogenic (DuPage and Bluestone, 2016) double-positive T cells in the former compared 
to the latter (Figure 2B). Fate mapping reporter studies for Th17 cells in this model of 
autoimmune inflammation have shown that these double-positive cells represent a 
transition phase during the ‘conversion’ of IL-17 single-positive into IFN-γ or GM-CSF 
double-positive T cells at the site of inflammation (Hirota et al., 2011). Consistent with 
these findings, AnxA1tg mice show a higher percentage of IL-17+ cells and a corresponded 
reduced percentage of IFN-γ (about 10% in AnxA1tg vs 18 % in control) and GM-CSF 
(about 16 % in AnxA1tg vs 20% in control) single-positive cells (Figure 2B). 
Increased basal anxiety-like behavior in AnxA1tg mice 
Direct observation of AnxA1tg mice in their cage revealed an altered behavior typified by 
an increased tendency to compulsive digging (compare Movie 1, wild type mice and 
Movie 2, AnxA1tg mice). Similar behavior was observed in the litters from the other 
founder (red line mice; compare Movie 3 of wild type mice with Movie 4 of AnxA1tg 
mice). Interestingly, the litter of red line mice also showed an increased level of hetero-
barbering (plucking of fur from cage-mates; Movie 5) - a behavior that has been proposed 
to represent a   model   of   human   trichotillomania   and   obsessive-compulsive 
spectrum disorders (Garner et al., 2004). To thoroughly measure this heightened anxious 
behavior, we used a battery of classical tests for anxiety behavior. The marble-burying test 
is used to measure digging (Taylor et al., 2017) and when applied to AnxA1tg  we 
quantified a significant increase in the number of buried marbles by the mice, which spent 
approximately double the time on this activity (Figure 3A). In the light and dark shuttle 
box test (Bourin and Hascoet, 2003) AnxA1tg mice spent in the lit area than the wild type 
counterpart, with a marked attenuation of numbers of crossings between the two 
compartments (Figure 3B). Significant behavioral differences were observed also in the 
climbing test- an experimental paradigm to measure vertical activity (Deacon and 
Rawlins, 2005) AnxA1tg mice showed an increased latency to the first climb and a 
significant reduction in the time spent on this activity (Figure 3C). All these changes were 
not secondary to a general impairment of locomotor activity as AnxA1tg mice showed no 
difference in the number of i) square crossed or ii) rearing as quantified in the open field 
test (Brooks and Dunnett, 2009) when compared to wild type animals (Figure 3D). This 
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heightened anxiety-like behavior was confirmed in the litters of the red line mice 
(Supplementary Figure 3B). 
Gene fingerprint of AnxA1tg whole brain reveals an increased expression of anxiety-
related genes  
CD4+ T cells exert a homeostatic control over a number of functions of the brain including 
learning,  memory and anxiety-like behavior (Filiano et al., 2016). In a previous study we 
have shown that CD4+ rather than CD8+ T cells revert the increased anxiety-like behavior 
observed in Rag-1-/- immunodeficient mice. Most interestingly, we have shown that the 
modulatory effects exerted by CD4+ T cells on behavior were ‘mirrored’ by specific 
changes in the gene fingerprint of the whole brain (Rattazzi et al., 2013). Thus, for 
instance, S100a10, a known biomarker for anxiety-like behavior, was up-regulated in 
RAG-1-/- and down-regulated to wild type level in RAG-1-/- mice where CD4+ T cells 
artificially re-introduced (RAG-1-/-/OT-II TCR transgenic mice). In light of these 
premises, we queried if AnxA1tg mice would also show changes in their brain gene 
fingerprint and performed a comparative analysis of gene expression of the whole brain 
using microarray analysis. The results showed significant differences in the level of 
expression of 15 genes of which 8 were unregulated and 7 downregulated in the whole 
brains of AnxA1tg mice in comparison to those of wild type mice (Figure 4A and 
Supplementary Table 1). Among these, several were associated with emotional disorders 
including alcoholism and anxiety such as erythroid differentiation regulator 1 (Erdr1) 
(Hovatta et al., 2005) and gamma-aminobutyric acid receptor subunit alpha-2 (Gabra2) 
(Engin et al., 2012) (Figure 4B) RT-PCR analysis of these genes on a larger number of 
samples confirmed these results with a down regulation of Erdr1 by about 78%  and an 
~3-fold upregulation of Gabra 2 (Figure 4C). Thus, the transgenic T cells can exert a 
tonic regulation on a discrete set of genes in the brain, even in the absence of any 
experimental manipulation.   
  
AnxA1tg CD4+ T cells express high level of a new anxiogenic factor named Immuno-
moodulin 
To identify the anxiogenic factor produced by AnxA1tg CD4+ T cells, we compared gene 
expression profiles of purified CD4+ T cells by microarray. In resting conditions, no 
statistical differences were observed between AnxA1tg and control CD4+ T cells (data not 
shown). However, in anti-CD3/CD28 stimulated cells, 8 genes were identified to be 
significantly modulated (Supplementary Table 2). Among those upregulated, AnxA1, 
interferon-inducible 203 and 2610019F03Rik (also called testis development related 
protein, Tdrp or C8orf42). We were intrigued by the last one as it encoded for a small 
protein of about 21kDa (like most of the cytokines) that was stored in vesicles (https://
www.proteinatlas.org/ENSG00000180190-TDRP/cell) and present in circulation (https://
genecards.weizmann.ac.il/v3/cgi-bin/carddisp.pl?gene=TDRP) and therefore decided to 
investigate its function. As we identified this gene in T cells and hypothesized that would 
be responsible for the anxious behavioral phenotype of AnxA1tg mice, we named it 
Immuno-moodulin (Imood).  
Next, we validated microarray results using immunoblotting and FACS intracellular 
staining of CD4+ T cells using a commercially available polyclonal antibody against 
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Imood. We first investigated Imood expression in resting or activated T cells from non-
transgenic C57BL/6 mice. In basal conditions, about 20% of cells express high levels of 
Imood. Activation of CD4+ T cells via the TCR caused a clear increase in the number of 
these cells with a doubling of their number (44%) following the triggering of both signal 1 
(anti-CD3) and signal 2 (anti-CD28) (Figure 5A). When we compared the expression of 
Imood in resting wild type and AnxA1tg CD4+ T cells (Figure 5B), it was possible to see 
an increase in the percentages of Imood-high cells in AnxA1tg mice compared to wild type 
(about 55% in AnxA1tg vs 35% in wild type) and their median fluorescence intensity 
(about 15 in AnxA1tg vs 7 in wild type). These differences tapered off but remained visible 
following activation with anti-CD3/CD28: about 80% of AnxA1tg cells expressed Imood 
with a median fluorescence intensity of 26 while about 70% wild type cells showed a 
median of 18. These results were confirmed at mRNA levels where it was possible to 
observe both the upregulation of Imood mRNA following activation of T cells with anti-
CD3/CD28 and an increased expression in AnxA1tg compared to wild type in both resting 
and stimulating conditions (Figure 5C). We confirmed these findings by western blot. 
Resting AnxA1tg CD4+ T cells showed increased levels of intracellular Imood compared to 
control (Figure 6D, Top panel). In addition, immunoprecipitation of Imood from the cell 
supernatant of wild type and AnxA1tg T cells in both resting and activated conditions 
showed an increased secretion of this protein in AnxA1tg T cells (Figure 5D, bottom 
panel).  
To explore the possible role of Imood in regulating anxiety behavior we administered the 
recombinant product of this gene (https://www.origene.com; Recombinant protein of 
human chromosome 8 open reading frame 42 [C8orf42], catalogue number TP313199) 
into wild type C57BL/6 mice. In all the experiments that followed, we used the light-dark 
shuttle box as a convenient screening test since this showed the highest difference between 
AnxA1tg and wild type mice. As shown in Supplementary Figure 5, mice injected with 
500ng of the intact (r-Imood) but not the denatured (95°C for 5min) protein (d-Imood) or 
PBS showed a significant increase in anxiety-like behavior. This change did not occur 
within hours of administration but started to be noticeable at day 3 post-injection (data not 
shown) and became highly significant at day 7. To confirm that Imood was indeed 
responsible for the increased anxiety-like behavior of AnxA1tg mice, we administered a 
commercially available polyclonal antibody against this protein (https://
www.novusbio.com/; catalogue number NBP1-93675) and control IgG to these mice. We 
also administered the same dose of antibodies and control IgG to wild type C57BL/6 to 
test its effect in control mice. As shown in Supplementary Figure 6, only AnxA1tg mice 
that received the polyclonal anti-Imood antibodies but not those receiving the control IgG 
showed a significant increase of the time in the light (by ~249%; p<0.001) and number of 
crossing (by ~194%; p<0.001). Interestingly, administration of the same antibody in wild 
type C57BL/6 mice also caused a significant increase in time in the light (by ~24%; 
p<0.05) and number of crossing (by ~76%; p<0.01) suggesting there may be an 
endogenous Imood level which might regulate basal anxiety behavior of mice.  
To further validate our hypothesis and increase specificity of action, we generated 
monoclonal antibodies against Imood using genetic immunization (Bates et al., 2006) 
(Supplementary Figure 7). Congruent with previous data, administration of highly 
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selective purified monoclonal anti-Imood antibodies 1B10 or 1C4 to AnxA1tg significantly 
increased the number of crossing (by ~123%, p<0.01 for 1C4; by ~178%, p<0.001 for 
1B10) and the time in the light (by ~208%, p<0.01 for 1C4; by ~396%, p<0.001 for 1B10) 
compared to IgG control. Thus, anti-Imood therapy rescues the phenotype of AnxA1tg 
back to that of wild type mice. 
Similar to what we observed with the polyclonal antibody, C57BL6 control mice 
administered with 1B10 and 1C4 showed significant increase in time in the light (by 
~75%, p<0.01 for 1C4; by ~86%, p<0.001 for 1B10) and number of crossings (by ~41%, 
p<0.05 for 1C4; by ~68%, p<0.001 for 1B10). Collectively this data reveals Imood as an 
innovative target for therapeutic strategies to treat anxiety behavior in mice (Figure 6A).  
Increased expression of Imood in OCD patients 
Finally, we searched for Imood expression in man. To this aim, we performed an initial 
retrospective screening of cDNA samples of PBMC obtained from obtained from 23 
patients that have been diagnosed with Obsessive-Compulsive Disorders and 20 healthy 
controls. Both sociodemographic (gender, education, employment and marital status) and 
clinical (duration of illness, duration of untreated illness, family history of psychiatric 
disorders, psychiatric comorbidity and current treatments) variables have been reported in 
Supplementary Table 3. As shown in Figure 6B, Imood expression was significantly 
higher (approximately 6-fold) than controls in both male and female subjects.  
Discussion  
A growing number of studies support the hypothesis that mood disorders can be driven by 
cellular and biochemical events that are rooted in the immune system (Dantzer, 2018; 
Haroon et al., 2012; Miller et al., 2017). This evidence emerged from several experimental 
studies investigating how both the depletion of T cells in mice (Cohen et al., 2006; Wolf et 
al., 2009) or the repopulation of lymphopenic mice with T cells alter brain functions 
including cognitions (Brynskikh et al., 2008; Kipnis et al., 2004), fear (Clark et al., 2014) 
and emotional states (Laumet et al., 2018; Rattazzi et al., 2013). Thus, in a study by Clark 
et al., CD4+ T cells conferred anxiolytic and antidepressant-like effects in Rag-2-/- mice 
(Clark et al., 2016). Using similar approaches, Brachman et al. and Scheinert et al. have 
shown that adoptive transfer of lymph node cells from chronically stressed mice were able 
to revert the anxious and depressive-like behavior of Rag-2-/- mice (Brachman et al., 2015; 
Scheinert et al., 2016).  
The modulatory effect of T cells on behavior has also been explored using effector disease 
relevant T cells. Seminal studies by Beurel and Jope have shown that the number of 
effector Th17 cells was significantly higher in the brain of mice exhibiting depressive-like 
behavior or in mice subjected to chronic restraint stress (Beurel et al., 2013; Beurel and 
Lowell, 2018; Beurel et al., 2018). In line with the studies mentioned above, the same 
group has shown that adoptively transferred Th17 cells in Rag-2-/- mice accumulated in the 
hippocampus of learned-helpless mice (Beurel et al., 2013). This work has provided key 
evidence that autoimmune effector T cells play a fundamental role in regulating 
pathological processes other than autoimmunity. In the context of this study, these findings 
have laid the foundations for a further exploration of the possible mechanisms linking 
autoimmunity and mental disorders. In addition, the lack of novel therapeutic 
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opportunities to treat mental health issues is very topical and we reason that detailed 
investigation of the mechanism(s) linking the immune system with behavioral responses 
could guide the development of new therapies.  
We reasoned about the existence of novel mechanism and plausibly un-identified factors 
while noting the behavioral phenotype of mice which single anomaly was higher 
expression of AnxA1 in T cells. This transgenic tool was generated to further investigate 
the specific properties of this mediator on the adaptive immune response (D'Acquisto, 
2009; D'Acquisto et al., 2007a; D'Acquisto et al., 2007b). In retrospective, our novel 
observations are aligned with the emerging notion that AnxA1 can regulate mental 
disorders. Genome-Wide Association Studies searches (GWAS Central at 
www.gwascentral.org) for AnxA1 reported about 62 studies on this protein and many of 
them on mental disorders. In fact, reports have shown a significant association between 
AnxA1 gene duplication and autism (Correia et al., 2014) or single nucleotide 
polymorphism in AnxA1 gene and schizophrenia(Clark et al., 2006) bipolar disorder or 
depression(Huang et al., 2010). Most intriguingly, all these conditions have been often 
linked to immune dysfunctions or inflammatory conditions (Muller, 2017; Prata et al., 
2017; Severance et al., 2018).    
 Moreover, AnxA1 is a ligand for the formyl peptide receptors (FPRs) (Bena et al., 2012; 
Cooray et al., 2013; Pederzoli-Ribeil et al., 2010). These prototype sensors of the innate 
immune system were initially identified as the cellular antenna for the capture of 
formylated peptides released by bacterial pathogens (Chen et al., 2017; Lee et al., 2017; 
Migeotte et al., 2006; Winther et al., 2018). Of interest, studies have shown that these 
receptors have more than one way to help the host sensing the danger. Their expression in 
the olfactory system allow mice to ‘sense’ the presence of infection-associated olfactory 
cues thus allowing animals to move away from the source of infection (Ackels et al., 
2014; Bufe et al., 2012; Stempel et al., 2016). Other lines of evidence support a role for 
FPR in regulating behaviour. Studies in knock out mice for both FPR1 and FPR2/ALX 
receptors have shown a significant reduction in anxiety (Gallo et al., 2014; Gao et al., 
2011) e.g. the opposite phenotype of AnxA1tg mice. Putting everything together, FPR may 
represent a prototype of signalling molecules that influence the behaviour of the host at 
both cellular and physical levels with the ultimate goal of preserving it from the 
challenges of the external environments (Dietschi et al., 2017).  
The anxiolytic effects of antibodies against Imood required days to be visible and 
statistically significant. A similarly delayed response was observed with recombinant 
Imood suggesting, in both cases, a downstream regulation of the expression of genes 
associated to anxiety rather than influencing directly the effects of neurotransmitters in the 
brain. The time-lag effect for the emergence of modulatory effects on anxiety, with 
AnxA1tg cells or following the administration of Imood, resonates well with the notion 
that classical drugs for the treatment of depression and anxiety present a delayed onset of 
5 to 7 days for their clinical efficacy to be apparent (Lam, 2012). Recent studies have put 
forward the proposition that delayed onset could be linked to the time needed for the 
immune system to respond and/or adapt to the administration of these drugs (Kiecolt-
Glaser et al., 2002), reinforcing the hypothesis that the immune system regulates the 
emotional state via a homeostatic control of the expression of genes with direct effect on 
emotions. 
Piras et al  Page !  of !  18 31
Our study opens a number of interesting and challenging questions that needs to be 
addressed. The first studies on Tdrp indicated a primary role in spermatogenesis (hence 
the name testis development-related protein) (Wang et al., 2010). However, further studies 
have shown that Tdrp-deficient mice were not significantly different from wild-type 
littermates in the development of testes, genitourinary tract, or sperm count. Tdrp 
deficiency alone was not sufficient to cause male infertility in mice (Mao et al., 2016). 
Consistent with this, administration of 1B10 and 1C4 in mice did not show any effects on 
male mice fertility or number of spermatocytes (data not shown). Combining all this 
information, it is possible to speculate that the protein has biological effects other than 
regulating spermatogenesis. At this regard, a very interesting study has recently shown 
that Tdrp is linked to mental disorders, including Attention-Deficit/Hyperactivity Disorder 
(ADHD) (Harich et al., 2019). The authors sought to validate the relevance of their finding 
in Drosophila but while they could find two orthologues for FBXO25, there was no 
orthologue for Tdrp. As Drosophila does not have an adaptive immune system, it is 
tempting to speculate that indeed Tdrp (Imood) might be a genuine ‘peripheral’ modulator 
of anxiety behaviour that is expressed in T cells. This is a rather interesting hypothesis that 
is corroborated by the fact that – to the best of our knowledge – Imood is not expressed in 
any invertebrate which are known to lack an adaptive immune system.   
This study provides solid foundations for future clinical and experimental work aimed at 
understanding how Imood might ultimately influence behavior. First of all, we would need 
to establish how Imood would enter the brain and what would be its receptor(s). Paradigm-
shifting work by Kipnis and collaborators have very recently ascribed the meningeal 
lymphatic as “a system capable of carrying fluid, immune cells, and macromolecules from 
the central nervous system” (Raper et al., 2016).This system has been proposed as the 
vascular network that allows the circulation and exchange of soluble contents between the 
brain cerebrospinal fluid and interstitial fluid (Da Mesquita et al., 2018; Herz et al., 2018) 
and could be therefore the entry door for Imood in the CNS.  
Another interesting perspective would be the existence of an Imood-specific mechanics of 
transport present in epithelial cells of the choroid plexus and in endothelial cells of the 
blood-brain barrier like in the case of leptin (Zlokovic et al., 2000). One surprising finding 
of our study is the existence of a small percentage of CD4+ T cells expressing high levels 
of Imood (Figure 6) and the increased number of these cells in the AnxA1tg mice. As 
transgenic mice are an experimental system that is artificially created to test a hypothesis, 
it will be very important in the future to confirm these findings in clinical samples and to 
further characterize and track these Imood-high T cells. Indeed, it is tempting to speculate 
that these Imood-high cells could specifically recirculate through the brain and thus be 
directly involved in the regulation of brain gene expression profile. This would be 
particularly intriguing as we have observed a readily upregulation of this protein following 
TCR stimulation. The constitutive activation state of autoimmune T cells might justify, at 
least in part, the increased incidence of mental disorders in patients suffering these 
diseases. All these hypotheses could only be validated through systematic screening for 
Imood expression at both protein and mRNA levels in a large cohort of patients, with 
different types of mental disorders as well.  
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The possibility that Imood could represent a novel fine tuner of mental disorders would 
also offer the opportunity to have a novel biomarker of prognostic and diagnostic value. 
This would enable patient stratification for the correct mental disorder (e.g. those 
associated with an immune component) or identification of the right patient subgroup for 
specific drug treatment. As such, for those with higher expression of Imood, a 
combinatorial therapy with immunomodulators and Imood neutralizing antibodies like 
1B10 might provide the unique opportunity to achieve a ‘healthy body in a healthy mind’. 
Along these lines, the identification of a protein mediator of emotional behavior and the 
availability of biological therapies that modulate its levels would represent a significant 
step forward for the treatment of mental disorders. Indeed, a biologic for the treatment of 
mental disorder would bypass several of the side effects associated with the daily 
administration of standard therapies mental disorders (Babic et al., 2010; Serretti and 
Chiesa, 2011; Uzun et al., 2010) as it would specifically act at the level of immune system 
rather than the CNS. 
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Figures and Tables 
Figure 1. Autoimmune-prone phenotype of T-cell specific AnxA1tg mice. (A) T cells 
from control and AnxA1tg mice were stimulated with the indicated concentration of 
plate-bound anti-CD3/CD28 for 16-18 hrs and then stained with anti-CD25 and 
anti-CD69 and analyzed by FACS. The numbers in the plot show the percentages 
of CD69 and CD25 double positive cells. Results are representative of n=12-18 
experiments with similar results. (B) T cells from control and AnxA1tg mice were 
stimulated with the indicated concentration of plate-bound anti-CD3/CD28 for 
24-30 hr and the supernatants used to measure the levels of IL-2. The bars show 
means ± SEM n=5 separate mice and are representative of five experiments with 
similar results. Statistical significance between control and AnxA1tg cells was 
determined by two-way ANOVA followed by Bonferroni multiple-comparison test 
** p<0.01; *** p<0.001; ****p<0.0001.  (C) Control and AnxA1tg mice were 
immunized with MOG35-55 and CFA and monitored daily for clinical signs of EAE 
(top left panel) or weight gain/loss (top right panel) for 23 days. Results show 
means ± SEM of n=8 mice per group and are representative of seven experiments 
with similar results. **** p<0.0001 (two-way ANOVA followed by Bonferroni 
multiple-comparison test) indicates significant values compared to wild type 
control mice. The spinal cord sections showed in the bottom left panels were 
obtained at day 18 and stained with hematoxylin and eosin as described in 
Materials and Methods. The table in the bottom right corner shows the number of 
mice showing a score of 2 at different times during the development of the EAE. 
(D) Control and AnxA1tg mice received an intraperitoneal injection of pristane to 
induce a lupus-like disease and were monitored daily for survival (left panel) or 
weight gain/loss (right panel) for 35 days. Results show means ± SEM of n=10 
mice per group and are representative of three experiments with similar results. 
*** p<0.001 (two-way ANOVA followed by Bonferroni multiple-comparison test) 
indicates significant values compared to wild type control mice.  
Figure 2. Phenotype of effector T cells recovered from AnxA1tg mice subjected to 
MOG35-55-induced EAE. Representative dot plots showing intracellular staining 
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for IL-17 and IFN-γ (top panels) or IL-17 and GM-CSF (bottom panels) of CD4+ T 
cells present in the draining lymph nodes (A) or spinal cords (B) of wild type and 
AnxA1tg T cells sacrificed at the indicated time after MOG35-55 immunization. The 
bar graphs at the bottom show the total cell number of CD45+ mononuclear cells 
recovered after Ficoll (draining lymph nodes) or Percoll (spinal cord) purification 
as described in the Supplementary Materials and Methods. The bar graphs 
referring to CD4+ T cells show the number of these cells present in the same 
tissues. Values are expressed as means ± SEM of n=6 mice for each group and are 
representative of three experiments with similar results. *p<0.05; **p<0.01 
(Student’s t-test) indicate significant values compared to wild type control mice. 
Figure 3. Increased signs of anxiety-like behavior in T cell-specific AnxA1tg mice. (A) 
The bar graphs show the total duration (seconds) of digging,  the latency (seconds) 
to the first digging bout and the total number of buried marbles during a 10-minute 
trial. (B) The bar graphs show the total time (seconds) spent in the lit area, latency 
(seconds) to first cross to the dark chamber and total number of crossings during a 
5-minute trial. (C) The bar graphs show, the total time (seconds) spent on the 
climbing mesh, the latency (seconds) to the first climb and the number of climbing 
events during a 5-minute trial. (D) The bar graphs show total number of squares 
crossed, the number of rears and the latency (seconds) to the first rear during a 5-
minute session. Values are expressed as means ± SEM of n=12 - 20 mice and are 
representative of four different experiments with similar results. * p<0.05, 
**p<0.01, ***p<0.001, ****p<0.0001 indicate significant values compared to 
wild type control mice (Mann–Whitney U-test).  
Figure 4. Gene fingerprint of the whole brain of T cell-specific AnxA1tg mice reveals 
several genes linked to anxiety-like behavior. (A) Summary of the gene 
expression profile of the whole brain of wild type and AnxA1tg mice showing the 
number of upregulated (FC>1) and downregulated (FC<1) differentially regulated 
genes (DEG). (B) Heatmap analysis on Microarray data of the whole brain of n=3 
wild type and AnxA1tg mice. The heatmap analysis used annotated genes only 
(genes with EntrezID). (C) Real time PCR analysis of two genes of interest 
selected from the microarray. Values are presented as individual data points ± SEM 
of n=8 mice.  
***p<0.001; ****p<0.0001 indicate significant values compared to wild type 
control mice (Student’s t-test). 
Figure 5.  Imood expression in AnxA1tg mice. (A) Imood intracellular staining of CD4+ 
T cells from C57BL/6 mice cultured overnight in complete medium (Control) or 
stimulated with 1µg/ml of plate-bound anti-CD3 or anti-CD3/CD28. The numbers 
in the gate represent the % of Imood-high expressing cells. The histograms show 
the results obtained with a single mouse and are representative or n=6-8 animals 
with similar results. (B) Imood intracellular staining of CD4+ T from wild type or 
AnxA1tg mice cultured overnight in complete medium (Control) or stimulated with 
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1µg/ml of anti-CD3/CD28. The numbers in the plots show the % of Imood-high 
expressing cells (in the brackets) and the median fluorescence intensity of the 
gated region. The histograms show the results obtained with a single mouse and 
are representative or n=6 animals with similar results. (C) RT-PCR of Imood 
expression in CD4+ T cells from wild type and AnxA1tg mice cultured overnight in 
complete medium (Control) or stimulated with 1µg/ml of plate-bound anti-CD3 or 
anti-CD3/CD28. Values are expressed as means ± SEM of n=6 mice. **p<0.01; 
***p<0.001 indicate significant values compared to wild type control mice 
(Student’s t-test).  (D) The top panel shows the western blotting of the whole cell 
lysates of indicated number of freshly isolated CD4+ T cells from wild type and 
AnxA1tg mice. The bottom panel shows the levels of Imood immunoprecipitated 
from the cell culture medium of CD4+ T cells from wild type and AnxA1tg mice 
cultured overnight in complete medium (Control) or stimulated with 1µg/ml of 
plate-bound anti-CD3 or anti-CD3/CD28. Membranes were immunoblotted with a 
polyclonal anti-Imood antibody and recombinant Imood (r-Imood) was used as 
control. The results shown are from a single mouse and are representative of six 
mice with similar results.  
Figure 6. Anxiolytic effects of anti-Immuno-moodulin antibodies. (A) AnxA1tg (grey 
bars) or C57BL/6 (white bars) mice received an intraperitoneal injection (100ng/
mouse) of anti-Imood antibodies 1B10 and 1C4 and then tested in the light and 
dark shuttle box test at day 7. The bar graphs show total number of crossings and 
the total time (seconds) spent in the lit area during a 5-minute trial. Values are 
expressed as means ± SEM of n=12 mice (AnxA1tg) or n=15 (C57BL/6) mice and 
are representative of three experiments with similar results. ****p<0.0001 indicate 
significant values compared with PBS-injected control mice (Mann–Whitney U-
test). (B) Real time PCR analysis of Imood in peripheral blood mononuclear cells 
of patients diagnosed with OCD as described in Materials and Methods. Values are 
presented as individual data points ± SEM of 23 patients and 20 healthy control. 
Male and female subjects are coded as shown in the graph.  
****p<0.0001 (Student’s t-test) (C) Schematic summery of the study showing how 
physiological levels of both AnxA1 and Imood play a homeostatic role regulating 
host immune response and emotional wellbeing. T cell activation causes the 
release of AnxA1 and the externalization of its receptor FPR. This signaling 
pathway integrates with the TCR and contributes to the regulation of the strength 
of TCR signaling and the level of T cell activation. Activated T cells express higher 
levels of Imood. The release of this protein by T cells contribute to a physiological 
state of lower mood that is similar to the sickness behavior observed following an 
infection. The increased level of expression of AnxA1 in T cells observed in 
patients suffering from autoimmune diseases is responsible for the lower threshold 
of T cell activation and the increased expression of Imood. The increased release of 
this protein in circulation leads to a state of higher anxiety and depression that is 
often observed in patients suffering from autoimmune conditions. 
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Supplementary Table 1. Differential gene expression profile whole brain from T cell 
specific AnxA1tg mice. The table shows a list of genes differentially modulated in 
AnxA1tg brain compared to wild type controls. Probe ID is affymetrix ID.  
Fold changes (FC) is logged value.  
Supplementary Table 2. Differential gene expression profile of CD4+ T cells from T 
cell specific AnxA1tg mice. The table shows a list of genes differentially 
modulated in AnxA1tg CD4+ T cells compared to wild type controls. Probe ID is 
Affymetrix ID.  
FC is logged value.  
Supplementary Table 3. Social and clinical variables of OCD subjects.  
Supplementary Table 4. List of antibodies used for FACS.  
Supplementary Figure 1. Generation of AnxA1tg mice. (A) Agarose gel electrophoresis 
of the AnxA1-Flag tagged construct cloned in two different backbone vectors 
(pCR2.1 and pcDNA3.1) and digested by SmaI to confirm the cloning of 1047 bp 
AnxA1 cDNA (indicated by the asterisk). (B) Schematic representation of the 
linearized construct that was used to generate T-cell specific AnxA1tg mice. The 
construct was inserted in the SmaI site of the VACD2 vector – just between the 
CD2 promoter sequence and CD2 locus control region (LCR) cassette. (C) The 
two agarose gels show the results of the PCR screening (for further details see 
Supplementary Material and Methods) of the 22 pups obtained from the pronuclear 
injection of VACD2-AnxA1-Flag construct. The top gels show the 3 mice that 
resulted positive for the transgene while the bottom show the PCR screening for 
the endogenous AnxA1 as control. (D) Western blotting of the whole cell lysate 
from purified equal number (1x106) of T cells of wild type and AnxA1tg mice 
showing increased expression of AnxA1 protein in transgenic mice. 
Supplementary Figure 2. Immune repertoire of AnxA1tg mice. (A) Representative dot 
plots showing CD4/CD8 staining of thymus, spleen and lymph node T cells of wild 
type and AnxA1tg T cells. (B) The bar graphs show the total cell number of cells 
purified from wild type and AnxA1tg mice as described in Supplementary Materials 
and Methods, section “Flow Cytometric analysis”. Values are expressed as means 
± SEM of n=6 mice for each group and are representative of four experiments with 
similar results. ****p<0.01 (Student’s t-test) indicates significant values compared 
to wild type control mice. 
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Supplementary Figure 3. Autoimmune-prone phenotype and heightened anxiety-like 
behavior AnxA1tg mice. (A) Control and AnxA1tg mice derived from the second 
founder (red line; see Results section for more details) were immunized with 
MOG35-55 and CFA and monitored daily for clinical signs of EAE (top left panel) 
or weight gain/loss (top right panel) for 23 days. Results show means ± SEM from 
n=10 mice per group and are representative of three separate experiments with 
similar results. **** p<0.001, (two-way ANOVA followed by Bonferroni multiple-
comparison test) indicates significant values compared to wild type control mice. 
(B) The bar graphs on the left show the total duration (seconds) of digging and 
total number of buried marbles, during a 10-minute trial of the marble burying test. 
Those in the middle show the total time (seconds) spent in the lit area and total 
number of crossing during a 5-minute trial in the light/dark shuttle box test. The 
bar on the right show total number of squares crossed and the latency (seconds) to 
the first rearing during a 5-minute session in the open field test. Values are 
expressed as means ± SEM of n=15 mice and are representative of three separate 
experiments with similar results. ***p<0.001; ****p<0.0001 indicate significant 
values compared to wild type control mice (Mann–Whitney U-test). 
Supplementary Figure 4.  Increased signs of organ inflammation in AnxA1tg 
subjected to pristane-induced lupus. Control and AnxA1tg mice received an 
intraperitoneal injection of pristane to induce a lupus-like disease. After 4 weeks 
mice were culled and dissected to collect spleens and lungs. Tissues were fixed 
with 4% PFA and then stained with hematoxylin and eosin. The panels in A show a 
photo picture of the spleen (left) and it relative histological section (right). The 
panels in B show a photo picture of the lung (left) and it relative histological 
sections (middle and right panels, 4x and 20x magnifications). Results are from a 
single mouse and are representative of n=10 mice with similar results.  
Supplementary Figure 5. Effect of recombinant Imood on anxiety-like behavior of 
C57BL/6 mice.  C57BL/6 mice were injected with PBS or r-Imood or denaturated 
r-Imood (d-Imood) (500ng, i.p.; https://www.origene.com; Recombinant protein of 
human chromosome 8 open reading frame 42 (C8orf42), catalogue number 
TP313199) and tested at day 7 post injection. The bar graphs show the total time 
(seconds) spent in the lit area and total number of crossings during a 5-minute trial. 
Values are expressed as means ± SEM of n=12 mice and are representative of three 
experiments with similar results. ****p<0.01 indicates significant values 
compared to PBS-injected control mice. §§p<0.01; §§§p<0.001 indicate significant 
values compared to d-Imood-injected mice. (Mann–Whitney U-test).  
Supplementary Figure 6. Effect of anti-Imood polyclonal antibody on anxiety-like 
behavior of C57BL/6 and AnxA1tg mice. C57BL/6 and AnxA1tg mice received 
an i.p. injection of polyclonal anti-Imood or IgG control antibodies (500ng i.p.) 
and then tested at day 7. The bar graphs show the total time (seconds) spent in the 
lit area and total number of crossings during a 5-minute trial. Values are expressed 
as means ± SEM of n=12 mice and are representative of three experiments with 
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similar results. ***p<0.001; ****p<0.0001 , indicate significant values compared 
to IgG-injected control mice (Mann–Whitney U-test).  
Supplementary Figure 7. Screening and identification of 1B10 and 1C4 monoclonal 
anti-Imood antibodies. (A) Aliquots (50ng) of recombinant Imood were loaded on 
an SDS-page gel and then transferred on PVDF membranes as detailed in 
Materials and Methods. Membranes were immunoblotted with the supernatants 
from different hybridoma cultures (code names indicated on the top of the top 
panel). Thereafter, the same membranes were stripped and immunoblotted with a 
commercially available anti-Imood antibody (bottom panel). (B) Aliquots (50ng) 
of recombinant Imood were immunoprecipitated with hybridoma supernatants and 
then loaded on an SDS-page gel as detailed in Materials and Methods. Membranes 
were immunoblotted with a commercially available anti-Imood antibody.  
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